BioSpace News Archive

Hoth Therapeutics, Inc. is pleased to announce that enrollment and dosing has begun for the second cohort in its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema.

Nektar Therapeutics (NASDAQ: NKTR) announced today that it will present data at two upcoming medical meetings for two of its cytokine immuno-oncology programs: IL-2 agonist, bempegaldesleukin (BEMPEG), and IL-15 agonist, NKTR-255.

Intensity Therapeutics, Inc. today announced that new breast cancer data from its phase 1/2 study IT-01 using novel lead asset, INT230-6, will be presented at the San Antonio Breast Cancer Symposium (SABCS) being held virtually and in-person at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 7-10, 2021.

AMF Medical is proud to announce that its Sigi™ Insulin Management System, for diabetes mellitus treatment, has met the criteria and has been granted Breakthrough Device Designation by the US Food and Drug Administration.

Seres Therapeutics, Inc. announced today that the first patient has been enrolled in the SER-155 Phase 1b study. SER-155 is an investigational, oral, cultivated microbiome therapeutic.

Labcorp (NYSE: LH), a global life sciences company, is now offering observed self-collection for COVID-19 PCR testing in more than 500 of its patient service centers (PSCs) nationwide for people without symptoms or known exposure.

Chest X-ray AI product developed by Enlitic, in collaboration with Konica Minolta, better detects major abnormal findings making a difference for radiologists and patients in Japan.

Cognition Therapeutics, Inc. will hold a virtual R&D symposium on December 7, 2021, from 10:00am – 12:00pm ET.

Oncology Pharma Inc. is a pioneering oncology company dedicated to providing the financing and the tools to license, develop, manufacture, and commercialize therapeutics.

CB Scientific. Inc. has announced it will convene a Special Stockholder Meeting in order to gain approval to implement a number of significant enhancements which management believes will better position CBSC to attain its stated business objectives.